2022

1. Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

   Breast Cancer Research and Treatment, Vol. 193, Núm. 1, pp. 95-103